manitimus

Manitimus is a synthetic small molecule immunosuppressant of the malononitrilamide class. It acts primarily by inhibiting de novo pyrimidine synthesis through selective blockade of dihydroorotate dehydrogenase (DHODH), an enzyme critical for lymphocyte proliferation. This results in suppression of both T-cell and B-cell function, leading to reduced immune response and prevention of graft rejection. Manitimus also exhibits anti-proliferative activity, inhibits tyrosine kinase activity, reduces endothelial adhesion molecule upregulation, and attenuates lymphocyte-endothelium interactions—key steps in transplant rejection. It was developed as a potential therapy for preventing acute and chronic allograft rejection in organ transplantation but its development has been discontinued after reaching Phase 2 clinical trials[1][2][3][4][5].

Brand names

manitimus

Other names

Manitimus [INN]FK 778FK778FK-778